In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats

References

• Ajmera A, Scherließ R. (2014). Stabilisation of proteins via mixtures of amino acids during spray drying. Int J Pharm 463:98–107.
   PubMed Web of Science ®Google Scholar
• Alhajj N, O'Reilly NJ, Cathcart H. (2021). Leucine as an excipient in spray dried powder for inhalation. Drug Discov Today 26:2384–96.
   PubMed Web of Science ®Google Scholar
• Barazesh A, Gilani K, Rouini M, Barghi MA. (2018). Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin. Eur J Pharm Sci 118:13–23.
   PubMed Web of Science ®Google Scholar
• Boraey MA, Hoe S, Sharif H, et al. (2013). Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol–water cosolvent system. Powder Technol 236:171–8.
   Web of Science ®Google Scholar
• Canestaro WJ, Forrester SH, Raghu G, et al. (2016). Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 149:756–66.
   PubMed Web of Science ®Google Scholar
• Carter NJ. (2011). Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 71:1721–32.
   PubMed Web of Science ®Google Scholar
• Chan HK, Clark A, Gonda I, et al. (1997). Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm Res 14:431–7.
   PubMed Web of Science ®Google Scholar
• Chen L, Okuda T, Lu X-Y, Chan H-K. (2016). Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev 100:102–15.
   PubMed Web of Science ®Google Scholar
• Chew NY, Tang P, Chan HK, Raper JA. (2005). How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 22:148–52.
   PubMed Web of Science ®Google Scholar
• Chow MYT, Qiu Y, Lo FFK, et al. (2017). Inhaled powder formulation of naked siRNA using spray drying technology with L-leucine as dispersion enhancer. Int J Pharm 530:40–52.
   PubMedGoogle Scholar
• Comeglio P, Filippi S, Sarchielli E, et al. (2017). Antifibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. J Steroid Biochem Mol Biol 168:26–37.
   PubMed Web of Science ®Google Scholar
• Comeglio P, Filippi S, Sarchielli E, et al. (2019). Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model. J Endocrinol Invest 42:283–94.
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, et al. (2014). Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 58:13–9.
   PubMed Web of Science ®Google Scholar
• Della Latta V, Cecchettini A, Del Ry S, Morales MA. (2015). Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res 97:122–30.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Vatanara A, Najafabadi AR, et al. (2014). The use of amino acids to prepare physically and conformationally stable spray-dried IgG with enhanced aerosol performance. Int J Pharm 466:163–71.
   PubMed Web of Science ®Google Scholar
• Feng AL, Boraey MA, Gwin MA, et al. (2011). Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm 409:156–63.
   PubMed Web of Science ®Google Scholar
• Gradon L, Sosnowski TR. (2014). Formation of particles for dry powder inhalers. Adv Powder Technol 25:43–55.
   Web of Science ®Google Scholar
• Hasija M, Li L, Rahman N, Ausar SF. (2013). Forced degradation studies: an essential tool for the formulation development of vaccines. VDT 3:11–33.
   Google Scholar
• Hilberg O, Simonsen U, du Bois R, Bendstrup E. (2012). Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. Clin Respir J 6:131–43.
   PubMed Web of Science ®Google Scholar
• Hopkinson CS, Cai W-J, Hu X. (2012). Carbon sequestration in wetland dominated coastal systems – a global sink of rapidly diminishing magnitude. Current Opinion in Environmental Sustainability 4:186–94.
   Web of Science ®Google Scholar
• Hübner RH, Gitter W, El Mokhtari NE, et al. (2008). Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44:507–11.
   PubMed Web of Science ®Google Scholar
• Hutchinson J, Fogarty A, Hubbard R, McKeever T. (2015). Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Sonnenberg A. (1990). The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology 98:380–6.
   PubMed Web of Science ®Google Scholar
• Kaewjan K, Srichana T. (2016). Nano spray-dried pyrazinamide-l-Leucine dry powders, physical properties and feasibility used as dry powder aerosols. Pharm Dev Technol 21:68–75.
   PubMed Web of Science ®Google Scholar
• Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. (2015). Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-κB, Muc5ac, TNF-α and IL-1β. Chem Biol Interact 237:151–65.
   PubMed Web of Science ®Google Scholar
• Kang JH, Kim YJ, Yang MS, et al. (2021). Co-spray dried nafamostat mesylate with lecithin and mannitol as respirable microparticles for targeted pulmonary delivery: pharmacokinetics and lung distribution in rats. Pharmaceutics 13:1519.
   PubMed Web of Science ®Google Scholar
• Kim C, Jeong SH, Kim J, et al. (2021). Evaluation of the long-term effect of polyhexamethylene guanidine phosphate in a rat lung model using conventional chest computed tomography with histopathologic analysis. PLoS One 16:e0256756.
   PubMed Web of Science ®Google Scholar
• Kwon YB, Kang JH, Han CS, et al. (2020). The effect of particle size and surface roughness of Spray-dried bosentan microparticles on aerodynamic performance for dry powder inhalation. Pharmaceutics 12:765.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kang JH, Lee HG, et al. (2016). Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols. Drug Des Devel Ther 10:4017–30.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kwon YB, Kang JH, et al. (2021). Inhaled bosentan microparticles for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. J Control Release 329:468–81.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Lee HG, Kwon YB, et al. (2018). The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation. Eur J Pharm Sci 117:279–89.
   PubMed Web of Science ®Google Scholar
• Ley B, Brown KK, Collard HR. (2014). Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 307:L681–L691.
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day BM, et al. (2017). Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 196:756–61.
   PubMed Web of Science ®Google Scholar
• Li X-W, Wu Y-H, Li X-H, et al. (2015). Role of eukaryotic translation initiation factor 3a in bleomycin-induced pulmonary fibrosis. Eur J Pharmacol 749:89–97.
   PubMed Web of Science ®Google Scholar
• Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. (2010). The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair 3:16.
   PubMedGoogle Scholar
• Mahmutovic Persson IF, Håkansson H, Örbom A, et al. (2020). Imaging biomarkers and pathobiological profiling in a rat model of drug-induced interstitial lung disease induced by bleomycin. Front Physiol 11:584.
   PubMed Web of Science ®Google Scholar
• Mangal S, Meiser F, Tan G, et al. (2015). Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations. Eur J Pharm Biopharm 94:160–9.
   PubMed Web of Science ®Google Scholar
• Mangal S, Park H, Nour R, et al. (2019). Correlations between surface composition and aerosolization of jet-milled dry powder inhaler formulations with pharmaceutical lubricants. Int J Pharm 568:118504.
   PubMedGoogle Scholar
• Marudamuthu AS, Bhandary YP, Fan L, et al. (2019). Caveolin-1–derived peptide limits development of pulmonary fibrosis. Sci Transl Med 11:eaat2848.
   PubMed Web of Science ®Google Scholar
• Meenach SA, Vogt FG, Anderson KW, et al. (2013). Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoyl phosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly (ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int J Nanomedicine 8:275–93.
   PubMed Web of Science ®Google Scholar
• Muhsin MD, George G, Beagley K, et al. (2016). Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation. Mol Pharm 13:1455–66.
   PubMed Web of Science ®Google Scholar
• Myllärniemi M, Kaarteenaho R. (2015). Pharmacological treatment of idiopathic pulmonary fibrosis–preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur Clin Respir J 2:26385.
   PubMed Web of Science ®Google Scholar
• Onoue S, Seto Y, Kato M, et al. (2013). Inhalable powder formulation of pirfenidone with reduced phototoxic risk for treatment of pulmonary fibrosis. Pharm Res 30:1586–96.
   PubMed Web of Science ®Google Scholar
• Park CW, Li X, Vogt FG, et al. (2013). Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm 455:374–92.
   PubMed Web of Science ®Google Scholar
• Park HJ, Jeong OY, Chun SH, et al. (2021). Butyrate improves skin/lung fibrosis and intestinal dysbiosis in bleomycin-induced mouse models. IJMS 22:2765.
   Google Scholar
• Pham DD, Grégoire N, Couet W, et al. (2015). Pulmonary delivery of pyrazinamide-loaded large porous particles. Eur J Pharm Biopharm 94:241–50.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Cavalli F, et al. (2016). Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Pulm Pharmacol Ther 40:95–103.
   PubMed Web of Science ®Google Scholar
• Rudd RM, Prescott RJ, Chalmers JC, et al. (2007). British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 62:62–6.
   PubMed Web of Science ®Google Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, et al. (2011). Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 20:85–97.
   PubMedGoogle Scholar
• Schafer MJ, White TA, Iijima K, et al. (2017). Cellular senescence mediates fibrotic pulmonary disease. Nat Commun 8:1–11.
   PubMed Web of Science ®Google Scholar
• Seto Y, Inoue R, Kato M, et al. (2013). Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B 120:44–51.
   PubMed Web of Science ®Google Scholar
• Seto Y, Suzuki G, Leung SS, et al. (2016). Development of an improved inhalable powder formulation of pirfenidone by spray-drying: in vitro characterization and pharmacokinetic profiling. Pharm Res 33:1447–55.
   PubMed Web of Science ®Google Scholar
• Shetty N, Park H, Zemlyanov D, et al. (2018). Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. Int J Pharm 544:222–34.
   PubMedGoogle Scholar
• Shoyele SA, Slowey A. (2006). Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J Pharm 314:1–8.
   PubMed Web of Science ®Google Scholar
• Sou T, McIntosh MP, Kaminskas LM, Prankerd RJ, et al. (2013). Designing a multicomponent spray-dried formulation platform for pulmonary delivery of biomacromolecules: the effect of polymers on the formation of an amorphous matrix for glassy state stabilization of biomacromolecules. Drying Technol 31:1451–8.
   Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. (2010). Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35:821–9.,
   PubMed Web of Science ®Google Scholar
• Trivedi R, Redente EF, Thakur A, et al. (2012). Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 23:505101.
   PubMed Web of Science ®Google Scholar
• Vehring R. (2008). Pharmaceutical particle engineering via spray drying. Pharm Res 25:999–1022.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu F, Xiang J, et al. (2021). A critical review of spray-dried amorphous pharmaceuticals: synthesis. Anal Appl 594:120165.
   Google Scholar
• Wang X, Wan W, Lu J, et al. (2021). Effects of L-leucine on the properties of spray-dried swellable microparticles with wrinkled surfaces for inhalation therapy of pulmonary fibrosis. Int J Pharm 610:121223.
   PubMedGoogle Scholar
• Wu YH, Li XW, Li WQ, et al. (2016). Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats. Eur J Pharmacol 773:42–50.
   PubMed Web of Science ®Google Scholar